



About GeoVax Labs, Inc

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against a wide range of infectious diseases and cancers using a novel, proprietary platform GV-MVA-VLP™.

GeoVax Labs, Inc.
Nasdaq: GOVX

Recent Stock Price (02/28/21)	\$5.10
Market Capitalization	\$32.2M
Shares Outstanding	6.3M
Fiscal Year End	Dec 31

September 25, 2020 Up-listed to Nasdaq and closed \$12.8M Public Offering

February 11, 2021 Closing of \$10.3M Follow-on Offering

Investment Highlights



Proprietary Vaccine Platform — produces noninfectious Virus-Like-Particles (VLPs) in a vaccinated individual with an extensive, clinically-proven safety profile, highly durable immune response; potential for single-dose, highly-effective vaccines, requiring minimal refrigeration storage.

COVID-19 Four vaccine candidates under development including a single-dose "universal" coronavirus vaccine and a vaccine for high-risk populations; proceeding through animal challenge testing; and preparation for human clinical testing. Data milestones expected H1 '21.

Immuno-oncology Program showing promising results; potential for multiple cancer indications; focused on advancing to clinical trials.

HIV Vaccine completed through Phase 2a; three clinical programs planned or in progress:

- Prevention (HVTN/NIH)
- Functional Cure (American Gene Technologies)
- Functional Cure (UCSF)

Single-dose 100% protection demonstrated with Ebola, Lassa, Marburg, and Sudan fever vaccines in IND-enabling studies; non-dilutive funding for completion of animal testing (non-human primates). Data milestones expected H1 '21.

Advancing Development Pipeline


	IND-enabling	Clinical Trials		Annual Commercial Opportunity
		Phase 1	Phase 2	
Immuno-Oncology				
Solid Tumors				> \$10 billion
HPV-associated Head and Neck Cancer				
Infectious Disease				
HIV (Preventive; HVTN)				> \$10 billion
HIV (Functional Cure; UCSF; AGT)				
Ebola, Lassa, Marburg, Sudan				\$100-\$500M
Zika Virus				\$100-\$500M
Malaria				\$500M-\$1 billion
Coronavirus (COVID-19)				> \$10 billion

COVID-19 Vaccine Program

Four vaccines GEO-CM01-04 designed; animal testing **results: H1 '21.**

Universal Coronavirus vaccine Focused on providing immunity to SARS-CoV-2 and seasonal coronavirus strains.

"Single-dose, universal coronavirus vaccine" for COVID-19, COVID-20, etc.



Advancing to Clinic

Focused on accelerating development into clinical testing.

No FDA requirement for toxicology testing expected.


Scale up for Emergency Use Authorization readiness during Phase 1a/1b clinical trial.

Immuno-oncology Program

Triple-threat Approach

- 1** Tumor antigen specific immune responses stimulated
- 2** Immune inhibition blocked with checkpoint inhibitors
- 3** Tumor cells killed using an oncolytic virus

GeoVax Concept for Cancer Immunotherapy



Tumor Regression

Stimulate MVA-VLP with tumor antigen to provoke immune system

Block Checkpoint inhibitor to reverse immune tolerance

Kill Achieve oncolysis using armed vaccinia virus

GeoVax - A Compelling Investment Opportunity

- Focused on areas of critical medical needs providing significant commercial opportunities;
- Clinical stage and IND-enabling programs successfully advancing;
- Novel, differentiated platform validated across infectious disease vaccines and immuno-oncology;
- New Filings Expands and Strengthens Intellectual Property Portfolio;
- Capital structure and balance sheet supporting advancing programs into milestone clinical development

Strong IP Protection

70
Granted
or pending patent applications spread over
20 patent families

IR Contact: Tristan Traywick
CORE IR / 377 Oak Street
Garden City, NY 11530
investor@geovax.com